Wouter Deelder is a Partner in Dalberg’s Geneva office and co-leads the firm’s Global Health Practice. He has nearly 25 years of experience as a strategy consultant, including nearly 20 years advising senior decision-makers in global health.
Wouter has led a broad range of engagements focused on the design and development of strategies and new initiatives. In the public health sector, his projects have included launching new initiatives to combat and control Malaria, Human African Trypanosomiasis, Onchocerciasis, and Lymphatic Filariasis; building market-shaping and innovative financing mechanisms such as the Affordable Medicines Facility-malaria (AMFm), and; developing new quantitative methods to support decision-makers with probabilistic supply and demand forecasting (e.g., http://www.vial-health.com).
Wouter also has deep experience supporting clients with the development, introduction, scale-up, uptake, and market-shaping for new global innovations, having worked on close to 20 new vaccines, drugs, tools, and diagnostics. He has also supported organizational transformations both inside and outside of the global health space.
Wouter has published in leading scientific journals on topics that include the application of advanced quantitative methods and machine learning in the fields of tuberculosis, malaria, and COVID-19.
Before joining Dalberg, Wouter worked as a strategy consultant for Bain & Company across Europe and the US.
Wouter completed his PhD in medical statistics and epidemiology at the London School of Hygiene and Tropical Medicine, focusing on the application of machine learning methods. He holds Master’s degrees in Management from the London School of Economics and in Economics from Erasmus University Rotterdam, and has certifications in data science from Harvard’s Extension School and innovative financing (as a Certified Alternative Investment Analyst).